Oxford Centre for Neuroinflammation

Dr Redwan Farooq
redwan.farooq@ndcn.ox.ac.uk

Request Access

Dataset ID	Description	Technology	Samples
EGAD50000003038	Raw FASTQ files from longitudinal CITE-seq on PBMC samples from a discovery cohort (n = 14) of treatment-naive pwMS commencing ocrelizumab. Samples were collected prior to commencing treatment (baseline), two weeks after the first ocrelizumab infusion (early) and immediately prior to each subsequent infusion (late), which were timed to coincide with the earliest detectable CD19+ B cell repopulation on monthly blood monitoring; for each individual, 3–5 longitudinal samples were obtained during treatment.	Illumina NovaSeq X Plus	42
EGAD50000003039	Raw FASTQ files from longitudinal CITE-seq on PBMC samples from a treatment-naive pwMS commencing ocrelizumab with poor therapeutic response despite depletion of CD19+ B cells below the lower limit of detection, experiencing breakthrough clinical disease activity and accumulation of disability (EDSS 2.0 to 6.0) over two years. Samples were collected two weeks after the first ocrelizumab infusion (early) and immediately prior to each subsequent infusion (late), which were timed to coincide with the earliest detectable CD19+ B cell repopulation on monthly blood monitoring; 4 longitudinal samples were obtained during treatment.	Illumina NovaSeq X Plus	2